Navigation Links
New prostate cancer screening test shows promise for diagnosis
Date:8/15/2011

CLEVELAND - A new prostate screening test developed by AnalizaDx, Inc., a Cleveland-based biotech company, and studied by researchers at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center along with colleagues at the Cleveland Clinic, the Veterans Administration Boston Healthcare and the National Cancer Institute, may prove to be a promising new tool in the diagnosis of prostate cancer. The study which will be published in the September issue of Urology found that this new screening test, the PSA/SIA assay, may be more sensitive in detecting prostate cancer than traditional screening methods.

"This has the potential to be a major advance in the development of more accurate tests for prostate cancer diagnosis," says Mark Stovsky, MD, Principal Investigator and lead author of the study, urologist at UH Case Medical Center and Associate Professor of Urology at Case Western Reserve University School of Medicine. "Prostate cancer is the most common cancer in men but traditional screening is not very accurate. This test provides a new way to look at prostate cancer diagnosis utilizing a novel biological assay which differentiates PSA molecular structures arising from cancer versus non-cancerous glands."

The accuracy of traditional prostate cancer screening (serum prostate-specific antigen or PSA) is limited by both relatively high false positive and false negative rates. Current diagnostic strategies that use total PSA to determine the need for biopsy demonstrate false positive rates of approximately 55-75 percent. This finding can therefore lead to unneeded prostate biopsies and unnecessary worry in patients. Additionally, the serum PSA test carries, in some studies, false negative rates of up to 15 percent, meaning that some men with 'normal' PSA values actually have cancer. What is needed is a test that can more accurately predict the presence of prostate cancer on biopsy.

Working with AnalizaDx, Inc., Dr. Stovsky and colleagues studied a urine-based test that works differently than most prostate screening methods by using a novel assay to separate PSA protein structures as being linked to either a 'cancer' or 'non-cancer' pathologic diagnosis based on ultrasound guided biopsy. Instead of attempting to find a single genetic biomarker which predicts the presence of cancer, the PSA/SIA assay is based on the assumption that there may be myriad different ultra-structural changes in the PSA protein which define the cancer phenotype. The authors theorize that the extremely high sensitivity of the test is the result of the ability of the PSA/SIA biological filter to categorize the myriad ultra-structural changes in the PSA protein as being made by either cancer versus non-cancer glands. The PSA/SIA assay was also found to have relatively high specificity (low false positive) results compared to the traditional serum PSA test.

The initial study, which followed 222 men, found that the new screening method had 100% sensitivity (no false negative results) and 80.3% specificity (low false positive results). The study data was collected at three clinical sites - UH Case Medical Center, VA Boston and Cleveland Clinic, and was analyzed at the National Cancer Institute.

"This new assay is a complete departure from how the scientific community has looked at biomarkers for cancer," says Arnon Chait, CEO of AnalizaDx, Inc. "Instead of just measuring levels of proteins, we are exploring changes in structure which are associated with cancer. This new method of diagnosing cancer truly has significant potential for other types of cancer as well."

The technology will be tested in further clinical research studies to determine its accuracy in serum as well as its ability to predict cancer grade/aggressiveness and the response to curative intent therapies. Study coauthors include Lee Ponsky, Srinivas Vourganti, Peter Stuhldreher, Mike Siroky, Victor Kipnis, Olga Fedotoff, Larissa Mikheeva, Boris Zaslavsky, Arnon Chait and J. Stephen Jones. The study is dedicated to the late Martin Resnick, MD, who served as the original Principal Investigator of this work and was Chairman of the Department of Urology at UH Case Medical Center and Case Western Reserve University School of Medicine.


'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5158
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Advance Toward Test for Aggressive Prostate Cancer
2. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
3. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
4. Few differences in outcomes between open and laparoscopic prostate surgery
5. Two Surgical Methods Equally Successful for Prostate Cancer
6. Genetic Mutation Linked to Prostate Cancer in Blacks
7. Statins May Benefit Prostate Cancer Patients
8. Demand For Mobile Prostate Cancer Brachytherapy Vendor Programs Continues Into 2010
9. Be a Star Athlete in the Fight Against Prostate Cancer
10. Do men with early prostate cancer commit suicide more frequently?
11. Effective prostate cancer treatment discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... The National ... the leading national organization representing the growing community of recovering individuals (now over ... include Family Recovery in policies addressing addiction. , Although many of the ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy ... of reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those ... the high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams ...
(Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from Pixel Film Studios ... Cut Pro X. Each user can select from up to 40 effect overlays. With ... focus offset, hue, saturation, value, contrast, glow, and more all within a click of ...
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises ... businesses. , The increasingly modern world of instantaneous consumption proves very convenient for ... sources such as oil and coal, which pollutes our air, water, and soil. It ...
(Date:2/13/2016)... ... 2016 , ... In its newly released Infusion Therapy Standards ... be used to ensure patient safety when placing an IV catheter. A key ... use of vein visualization technology in patients with difficult venous access or after ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Clinical Affairs leaders at pharmaceutical organizations are looking ... of the world. While some companies have conducted a significant number ... activity in countries such as India and ... and India are now requiring local ... countries. --> China and ...
(Date:2/12/2016)... , Feb. 12, 2016   National Community Pharmacists ... RPh, MBA issued the following statement today in response ... by the Centers for Medicare & Medicaid Services ... NCPA, beneficiary advocates and others: patient advocacy ... are still reviewing the full CMS analysis. Our initial ...
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
Breaking Medicine Technology: